Brent at $117 Already Tops the World Bank Crisis Forecast
The World Bank's October outlook puts 2026 Brent at $91 and a 2027 crisis case at $105. December futures just printed $117.38, so the worst-case commodity shock is already in the tape.
The World Bank's October outlook puts 2026 Brent at $91 and a 2027 crisis case at $105. December futures just printed $117.38, so the worst-case commodity shock is already in the tape.
Alphabet posted negative $9.1 billion in free cash flow even as revenue jumped 25% and Google Cloud more than doubled. Capex hit $51.4 billion, funded with new debt and shares.
The Fed held rates at 3-3/4 to 4 percent in a 10-2 vote, with Lisa Cook and Beth Hammack preferring another quarter-point hike. The split now frames the December 8-9 meeting.
The Bank of Canada raised its policy rate 25 basis points to 2.5%, its first hike since 2023, betting that early action stops a gasoline price shock from spreading into broader inflation.
Guidewire will pay $1.7 billion in cash, plus up to $400 million more, for hyperexponential, an AI-native pricing firm. The core-systems vendor is buying a decision engine and funding part of it with new debt.
French 10-year borrowing costs crossed 5% and briefly overtook U.S. Treasuries for the first time since 2013. A ratings reprieve slowed the rout for a day; a budget vote now decides whether the wait was warranted.
HealthSpan Partners, an affiliate of Catholic nonprofit Bon Secours Mercy Health, agreed to acquire Surgery Partners for about $5.7 billion, with Bain Capital rolling its stake forward rather than cashing out.
GSK's Hibsago won FDA approval as the first functional-cure option for chronic hepatitis B, but only about one in five eligible patients achieved durable control, and the label carries a boxed warning.
Schneider Electric raised €6 billion selling new shares with no preemptive rights, the equity slice of its $22.6 billion cash takeover of industrial-software maker PTC, plus up to €17 billion in new debt.
AstraZeneca's Ultomiris won accelerated FDA approval to reduce proteinuria in IgA nephropathy, becoming the first C5 inhibitor in the space. But unlike Novartis's fully approved Fabhalta, it has not yet shown it preserves kidney function.
IBM posted $17.1 billion in third-quarter revenue as software grew 8 percent. Free cash flow improved, and the company raised its full-year cash outlook, while debt rose to $63.8 billion.
An FDA approval could let a biomarker-defined subset of rectal cancer patients skip chemotherapy, radiation, and surgery, but the broader pivotal data land short of the famous 100% single-center result.